Fetal Valproate Syndrome - Quest Diagnostics Patient Health Library

Fetal Valproate Syndrome

Important
It is possible that the main title of the report Fetal Valproate Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

Dalpro, Fetal Effects From
Depakene, Fetal Effects From
Depakote Sprinkle, Fetal Effects From
Depakote, Fetal Effects From
Divalproex, Fetal Effects From
Epival, Fetal Effects From
Myproic Acid, Fetal Effects From
Valproic Acid, Fetal Effects From
Fetal Anti-Convulsive Syndrome

Disorder Subdivisions

None

General Discussion

Fetal Valproate Syndrome is a rare congenital disorder caused by exposure of the fetus to valproic acid (dalpro, depakene, depakote, depakote sprinkle, divalproex, epival, myproic acid) during the first three months of pregnancy. Valproic acid is an anticonvulsant drug used to control certain types of seizures in the treatment of epilepsy. A small percentage of pregnant women who take this medication can have a child with Fetal Valproate Syndrome. The exact prevalence of this condition remains to be established. Symptoms of this disorder may include spina bifida, distinctive facial features, and other musculoskeletal abnormalities.

Resources

Spina Bifida Association of America
4590 MacArthur Boulevard NW
Suite 250
Washington, DC 20007-4226
Tel: (202)944-3285
Fax: (202)944-3295
Tel: (800)621-3141
Email: sbaa@sbaa.org
Internet: http://www.sbaa.org

International Federation for Spina Bifida and Hydrocephalus
Attn. Els De Clercq
Cellebroersstraat 16
B-1000
Brussels, B1000
Brussels
Email: info@ifglobal.org
Internet: http://www.ifglobal.org

Spina Bifida and Hydrocephalus Association of Canada
#977-167 Lombard Avenue
Winnipeg, Manitoba, R3B 0V3
Canada
Tel: 204-925-3650
Fax: 204-925-3654
Tel: 800-565-9488
Email: spinab@mts.net
Internet: http://www.sbhac.ca

National Fetal AntiConvulsant Syndrome Association
P.O. Box 7416
Annan, Intl DG12 5ET
United Kingdom
Tel: 01 461 206 870
Fax: 01 461 206 870
Email: facsline3@aol.com
Internet: http://www.facsline.org

Organization For Anti-Convulsant Syndrome
PO Box 772
Pilling
Preston, Intl PR3 6WW
UK
Tel: 01253 790000
Fax: 01253 790000
Email: Janet.oacs@btinternet.com
Internet: http://www.oacs-uk.co.uk/

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc. ® (NORD). A copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html

The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report.
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org
Last Updated: 4/25/2008
Copyright 1994, 2003 National Organization for Rare Disorders, Inc.

Go to top of page

This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.